Fig. 1
From: Validation of a potency assay for CD34 + cell based therapy
Quantification of VEGF in the supernatant of ProtheraCytes cultures as a potency assay. (A) (C) Concentration of VEGF in cell culture supernatants after 9 days of CD34 + cell expansion from four healthy donors and 16 AMI patients (Phase I/IIb clinical trial). (B) No significant difference observed when VEGF concentration was compared between AMI patients and healthy donors, but a significant difference was observed between AMI patients and StemFeed culture medium as negative control (t-test, p = 0.0021). (D) No significant difference (t-test, p = 0.0670) when VEGF concentrations in AMI patient and healthy donor supernatants quantified with the conventional method (Human VEGF QuantiGlo ELISA) were compared to those quantified with the ELLA system and its VEGF cartridge. These results have also been normalized to the number of CD34 + cells obtained after expansion and can be found in Supplemental Fig. 1.
